Kornelia M Kliś, Roger M Krzyżewski, Borys M Kwinta, Krzysztof Stachura, Tadeusz J Popiela, Igor Szydłowski, Bartłomiej Łasocha, Tomasz Grodzicki, Jerzy Gąsowski
{"title":"Can β-blockers prevent intracranial aneurysm rupture?: insights from Computational Fluid Dynamics analysis.","authors":"Kornelia M Kliś, Roger M Krzyżewski, Borys M Kwinta, Krzysztof Stachura, Tadeusz J Popiela, Igor Szydłowski, Bartłomiej Łasocha, Tomasz Grodzicki, Jerzy Gąsowski","doi":"10.1093/cvr/cvae158","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Hypertension is a risk factor for intracranial aneurysm rupture. We analysed whether the intake of drugs from specific classes of anti-hypertensive medications affects haemodynamic parameters of intracranial aneurysm dome.</p><p><strong>Methods and results: </strong>We recorded medical history including medications and the in-hospital blood pressure values. We then obtained 3D reconstruction of each patients' aneurysm dome and the feeding artery. Using OpenFOAM software, we performed Computational Fluid Dynamics analysis of blood flow through the modelled structures. Blood was modelled as Newtonian fluid, using the incompressible transient solver. As the inlet boundary condition, we used the patient-specific Internal Carotid Artery blood velocity waves obtained with Doppler ultrasound. We calculated haemodynamic parameters of the aneurysm dome. All presented analyses are cross-sectional. We included 72 patients with a total of 91 unruptured intracranial aneurysms. The history of β-blocker intake significantly influenced haemodynamic parameters of aneurysm dome. The patients on β-blockers had significantly smaller aneurysm domes (5.09 ± 2.11 mm vs. 7.41 ± 5.89 mm; P = 0.03) and did not have aneurysms larger than 10 mm (0% vs. 17.0%; P = 0.01). In the Computational Fluid Dynamics analysis, walls of aneurysms in patients who took β-blockers were characterized by lower Wall Shear Stress Gradient (1.67 ± 1.85 Pa vs. 4.3 ± 6.06 Pa; P = 0.03), Oscillatory Shear Index (0.03 ± 0.02 vs. 0.07 ± 0.10; P = 0.04), and Surface Vortex Fraction (16.2% ± 5.2% vs. 20.0% ± 6.8%; P < 0.01). After controlling for covariates, we demonstrated difference of Surface Vortex Fraction (F[1, 48] = 4.36; P = 0.04) and Oscillatory Shear Index (F[1, 48] = 6.51; P = 0.01) between patients taking and not taking β-blockers, respectively.</p><p><strong>Conclusion: </strong>Intake of β-blockers might contribute to more favourable haemodynamics inside aneurysmal sac. Other anti-hypertensive medication classes were not associated with differences in intracranial aneurysm parameters.</p>","PeriodicalId":9638,"journal":{"name":"Cardiovascular Research","volume":" ","pages":"2408-2419"},"PeriodicalIF":10.2000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/cvr/cvae158","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Aims: Hypertension is a risk factor for intracranial aneurysm rupture. We analysed whether the intake of drugs from specific classes of anti-hypertensive medications affects haemodynamic parameters of intracranial aneurysm dome.
Methods and results: We recorded medical history including medications and the in-hospital blood pressure values. We then obtained 3D reconstruction of each patients' aneurysm dome and the feeding artery. Using OpenFOAM software, we performed Computational Fluid Dynamics analysis of blood flow through the modelled structures. Blood was modelled as Newtonian fluid, using the incompressible transient solver. As the inlet boundary condition, we used the patient-specific Internal Carotid Artery blood velocity waves obtained with Doppler ultrasound. We calculated haemodynamic parameters of the aneurysm dome. All presented analyses are cross-sectional. We included 72 patients with a total of 91 unruptured intracranial aneurysms. The history of β-blocker intake significantly influenced haemodynamic parameters of aneurysm dome. The patients on β-blockers had significantly smaller aneurysm domes (5.09 ± 2.11 mm vs. 7.41 ± 5.89 mm; P = 0.03) and did not have aneurysms larger than 10 mm (0% vs. 17.0%; P = 0.01). In the Computational Fluid Dynamics analysis, walls of aneurysms in patients who took β-blockers were characterized by lower Wall Shear Stress Gradient (1.67 ± 1.85 Pa vs. 4.3 ± 6.06 Pa; P = 0.03), Oscillatory Shear Index (0.03 ± 0.02 vs. 0.07 ± 0.10; P = 0.04), and Surface Vortex Fraction (16.2% ± 5.2% vs. 20.0% ± 6.8%; P < 0.01). After controlling for covariates, we demonstrated difference of Surface Vortex Fraction (F[1, 48] = 4.36; P = 0.04) and Oscillatory Shear Index (F[1, 48] = 6.51; P = 0.01) between patients taking and not taking β-blockers, respectively.
Conclusion: Intake of β-blockers might contribute to more favourable haemodynamics inside aneurysmal sac. Other anti-hypertensive medication classes were not associated with differences in intracranial aneurysm parameters.
目的:高血压是颅内动脉瘤破裂的危险因素之一。我们分析了服用特定类别的抗高血压药物是否会影响颅内动脉瘤穹隆的血流动力学参数:我们记录了包括药物在内的病史和院内血压值。然后,我们对每位患者的动脉瘤穹顶和供血动脉进行了三维重建。我们使用 OpenFOAM 软件对流经模型结构的血流进行了计算流体力学分析。使用不可压缩瞬态求解器将血液模拟为牛顿流体。作为入口边界条件,我们使用了通过多普勒超声获得的患者特定颈内动脉血流速度波。我们计算了动脉瘤穹顶的血流动力学参数。所有分析均为横断面分析。我们纳入了 72 名患者,共 91 个未破裂的颅内动脉瘤。服用β-受体阻滞剂的病史对动脉瘤穹顶的血液动力学参数有显著影响。服用β-受体阻滞剂的患者动脉瘤穹顶明显较小(5.09 ± 2.11 mm vs. 7.41 ± 5.89 mm; p = 0.03),且动脉瘤不超过 10 mm (0% vs. 17.0%; p = 0.01)。在计算流体动力学分析中,服用β-受体阻滞剂患者的动脉瘤壁具有较低的壁剪应力梯度(1.67 ± 1.85 Pa vs. 4.3 ± 6.06 Pa; p = 0.03)、振荡剪切指数(0.03 ± 0.02 vs. 0.07 ± 0.10; p = 0.04)和表面涡流分率(16.2% ± 5.2% vs. 20.0% ± 6.8%; p结论:服用β-受体阻滞剂可能有助于改善动脉瘤囊内的血液动力学。其他降压药物类别与颅内动脉瘤参数的差异无关。
期刊介绍:
Cardiovascular Research
Journal Overview:
International journal of the European Society of Cardiology
Focuses on basic and translational research in cardiology and cardiovascular biology
Aims to enhance insight into cardiovascular disease mechanisms and innovation prospects
Submission Criteria:
Welcomes papers covering molecular, sub-cellular, cellular, organ, and organism levels
Accepts clinical proof-of-concept and translational studies
Manuscripts expected to provide significant contribution to cardiovascular biology and diseases